Trial
NCT03437720
Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
—
Condition
Non-alcoholic Steatohepatitis
Intervention
SAR425899
Why stopped
Sponsor decision to cancel TRIAL, not related to safety concern.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-04-13